Precision BioSciences (DTIL) Competitors

$6.45 -0.41 (-5.98%)

Closing price 06/10/2026 04:00 PM Eastern

Extended Trading

$6.47 +0.02 (+0.31%)

As of 04:01 AM Eastern

DTIL vs. RLMD, REPL, ANRO, ZVRA, and CRMD

Should you buy Precision BioSciences stock or one of its competitors? MarketBeat compares Precision BioSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precision BioSciences include Relmada Therapeutics (RLMD), Replimune Group (REPL), Alto Neuroscience (ANRO), Zevra Therapeutics (ZVRA), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.

How does Precision BioSciences compare to Relmada Therapeutics?

Precision BioSciences (NASDAQ:DTIL) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Precision BioSciences has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Precision BioSciences currently has a consensus price target of $32.25, suggesting a potential upside of 400.00%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 88.09%. Given Precision BioSciences' higher possible upside, equities analysts plainly believe Precision BioSciences is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Precision BioSciences has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	4.86	-$45.72M	-$3.67	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Precision BioSciences had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 2 mentions for Precision BioSciences and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.89 beat Precision BioSciences' score of 1.44 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Positive
Relmada Therapeutics	Very Positive

Relmada Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Relmada Therapeutics' return on equity of -71.22% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Relmada Therapeutics beats Precision BioSciences on 8 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Precision BioSciences has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Precision BioSciences	$34.26M	4.86	-$45.72M	-$3.67	N/A

Replimune Group has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Replimune Group had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Replimune Group and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.44 beat Replimune Group's score of 0.44 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Replimune Group	Neutral
Precision BioSciences	Positive

Replimune Group presently has a consensus target price of $4.88, suggesting a potential downside of 42.44%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 400.00%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Replimune Group has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Summary

Precision BioSciences beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Alto Neuroscience has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Precision BioSciences has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Precision BioSciences	$34.26M	4.86	-$45.72M	-$3.67	N/A

38.0% of Precision BioSciences shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Precision BioSciences had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 2 mentions for Precision BioSciences and 0 mentions for Alto Neuroscience. Precision BioSciences' average media sentiment score of 1.44 beat Alto Neuroscience's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Precision BioSciences	Positive

Alto Neuroscience has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Alto Neuroscience's return on equity of -47.22% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Alto Neuroscience presently has a consensus target price of $35.25, suggesting a potential upside of 79.35%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 400.00%. Given Precision BioSciences' higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Precision BioSciences beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Zevra Therapeutics presently has a consensus target price of $29.29, suggesting a potential upside of 116.93%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 400.00%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Zevra Therapeutics had 12 more articles in the media than Precision BioSciences. MarketBeat recorded 14 mentions for Zevra Therapeutics and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.44 beat Zevra Therapeutics' score of 0.47 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Precision BioSciences	Positive

Zevra Therapeutics has a net margin of 101.58% compared to Precision BioSciences' net margin of -96.73%. Zevra Therapeutics' return on equity of 51.49% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.50	$83.23M	$1.99	6.78
Precision BioSciences	$34.26M	4.86	-$45.72M	-$3.67	N/A

Summary

Zevra Therapeutics beats Precision BioSciences on 11 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

34.2% of CorMedix shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CorMedix has a net margin of 45.25% compared to Precision BioSciences' net margin of -96.73%. CorMedix's return on equity of 45.57% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Precision BioSciences	-96.73%	-85.37%	-37.34%

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 71.04%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 400.00%. Given Precision BioSciences' higher probable upside, analysts clearly believe Precision BioSciences is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

CorMedix has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.21	$163.05M	$2.13	4.12
Precision BioSciences	$34.26M	4.86	-$45.72M	-$3.67	N/A

CorMedix has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

In the previous week, CorMedix had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for CorMedix and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.44 beat CorMedix's score of 0.47 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Neutral
Precision BioSciences	Positive

Summary

CorMedix beats Precision BioSciences on 12 of the 16 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTIL vs. The Competition

Export

Metric	Precision BioSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$177M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.32%	2.67%	5.61%
P/E Ratio	-1.76	18.83	24.41	23.63
Price / Sales	4.86	294.36	502.20	102.41
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	1.60	8.00	10.30	6.70
Net Income	-$45.72M	$23.89M	$3.56B	$337.26M
7 Day Performance	0.62%	-5.43%	-2.93%	-2.43%
1 Month Performance	-17.94%	-4.18%	-0.36%	0.19%
1 Year Performance	27.22%	36.70%	20.08%	23.16%

Precision BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTIL Precision BioSciences	2.7398 of 5 stars	$6.45 -6.0%	$32.25 +400.0%	+24.0%	$177M	$34.26M	N/A	200	Positive News Analyst Forecast
RLMD Relmada Therapeutics	2.3127 of 5 stars	$6.36 -7.1%	$12.00 +88.6%	+705.4%	$718.50M	N/A	N/A	10	Positive News
REPL Replimune Group	1.2937 of 5 stars	$8.87 -1.5%	$4.88 -45.0%	-16.4%	$717.56M	N/A	N/A	210	Gap Down
ANRO Alto Neuroscience	1.8323 of 5 stars	$18.76 -4.7%	$35.25 +87.9%	+648.7%	$704.34M	N/A	N/A	N/A
ZVRA Zevra Therapeutics	4.3799 of 5 stars	$10.89 -5.3%	$23.33 +114.4%	+45.5%	$679.23M	$122.29M	5.56	20	Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTIL) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Competitors

DTIL vs. RLMD, REPL, ANRO, ZVRA, and CRMD

How does Precision BioSciences compare to Relmada Therapeutics?

Summary

How does Precision BioSciences compare to Replimune Group?

Summary

How does Precision BioSciences compare to Alto Neuroscience?

Summary

How does Precision BioSciences compare to Zevra Therapeutics?

Summary

How does Precision BioSciences compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Competitors

DTIL vs. RLMD, REPL, ANRO, ZVRA, and CRMD

How does Precision BioSciences compare to Relmada Therapeutics?

Which has more risk and volatility, DTIL or RLMD?

Do analysts prefer DTIL or RLMD?

Which has preferable earnings and valuation, DTIL or RLMD?

Do insiders & institutionals hold more shares of DTIL or RLMD?

Does the media refer more to DTIL or RLMD?

Is DTIL or RLMD more profitable?

Summary

How does Precision BioSciences compare to Replimune Group?

Which has better valuation & earnings, REPL or DTIL?

Which has more volatility & risk, REPL or DTIL?

Do insiders and institutionals hold more shares of REPL or DTIL?

Does the media prefer REPL or DTIL?

Do analysts recommend REPL or DTIL?

Is REPL or DTIL more profitable?

Summary

How does Precision BioSciences compare to Alto Neuroscience?

Which has more risk and volatility, ANRO or DTIL?

Which has higher valuation & earnings, ANRO or DTIL?

Do institutionals and insiders hold more shares of ANRO or DTIL?

Does the media prefer ANRO or DTIL?

Is ANRO or DTIL more profitable?

Do analysts rate ANRO or DTIL?

Summary

How does Precision BioSciences compare to Zevra Therapeutics?

Do analysts prefer ZVRA or DTIL?

Do institutionals & insiders have more ownership in ZVRA or DTIL?

Does the media prefer ZVRA or DTIL?

Is ZVRA or DTIL more profitable?

Which has more risk and volatility, ZVRA or DTIL?

Which has higher earnings & valuation, ZVRA or DTIL?

Summary

How does Precision BioSciences compare to CorMedix?

Do institutionals and insiders have more ownership in CRMD or DTIL?

Is CRMD or DTIL more profitable?

Do analysts recommend CRMD or DTIL?

Which has higher earnings and valuation, CRMD or DTIL?

Which has more risk and volatility, CRMD or DTIL?

Does the media prefer CRMD or DTIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools